Drugs & Targets FDA grants PYX-201 Orphan Drug Designation in pancreatic cancer May 12, 2023Vol.49 No.19
Drugs & Targets Leal Health establishes AI platform to match cancer patients with relevant treatment options May 12, 2023Vol.49 No.19
Drugs & Targets FDA approves xT CDx, an NGS-based in vitro diagnostic device May 05, 2023Vol.49 No.18
Drugs & Targets FDA releases draft guidance on decentralized clinical trials May 05, 2023Vol.49 No.18
Drugs & Targets FDA accepts sBLA and EMA validates Reblozyl as first-line treatment of anemia in lower risk MDS May 05, 2023Vol.49 No.18
Drugs & Targets FDA grants Fast Track designation for ¹⁷⁷Lu-PNT2002 for metastatic castration-resistant prostate cancer April 28, 2023Vol.49 No.17
Drugs & Targets MD Anderson and Generate: Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI April 28, 2023Vol.49 No.17
